ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
135.48
+0.90 (+0.67%)
As of 11:47AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close134.58
Open133.94
Bid135.27 x 800
Ask135.34 x 900
Day's Range133.78 - 136.36
52 Week Range102.10 - 149.34
Volume423,610
Avg. Volume1,557,952
Market Cap30.144B
Beta1.18
PE Ratio (TTM)58.27
EPS (TTM)2.33
Earnings DateJul 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est158.89
Trade prices are not sourced from all markets
  • J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
    Zacks2 hours ago

    J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

  • Roche's Flu Drug Meets Primary Endpoint in Phase III Study
    Zacks3 hours ago

    Roche's Flu Drug Meets Primary Endpoint in Phase III Study

    Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.

  • Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert
    Zacks4 hours ago

    Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert

    Alexion Pharmaceuticals, Inc. (ALXN) is looking like an interesting pick from a technical perspective

  • Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
    Zacksyesterday

    Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

    FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Investopedia8 days ago

    4 Biotechs on Verge of Big Breakouts

    The large-cap biotech stocks have been left in the dust this year with the iShares Nasdaq Biotechnology ETF ( IBB) rising by only 8.7%. This, by most standards, is a healthy gain compared to the S&P 500 rise of only 3%. Signs are emerging that the larger-cap biotechs are poised to break out in the near term, and that could send stocks like Celgene Corp. ( CELG), Gilead Sciences, Inc. ( GILD), Amgen Inc. ( AMGN) and Alexion Pharmaceuticals, Inc. ( ALXN) much higher.

  • Analysts Are Mostly Feeling Good about Vertex Pharmaceuticals
    Market Realist12 days ago

    Analysts Are Mostly Feeling Good about Vertex Pharmaceuticals

    In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96, which represented a ~7% rise from its previous week’s close of $159.76. On June 29, Vertex Pharmaceuticals’ stock price rose 15.16% to reach $169.96 from its previous day’s close of $147.59. In June, Vertex Pharmaceuticals announced that its cystic fibrosis drug Orkambi would be reimbursed in Sweden.

  • 3 Big Stock Charts for Thursday: Express Scripts Holding Co, Alexion Pharmaceuticals and Ventas
    InvestorPlace12 days ago

    3 Big Stock Charts for Thursday: Express Scripts Holding Co, Alexion Pharmaceuticals and Ventas

    Traders looking for higher-odds trading prospects, however, will want to look at Express Scripts Holding Co (NASDAQ:ESRX), Alexion Pharmaceuticals (NASDAQ:ALXN) and Ventas (NYSE:VTR) … each of which are actually getting into a bullish groove despite Tuesday’s lull. The wave of M&A within the healthcare arena, and within the pharmaceutical distribution sliver of the market in particular, has been a blessing and a curse for Express Scripts Holding. • The monthly chart indicates that the bullish move in December not only broke above a falling resistance line that had extended back to 2015’s peak, but has put a string of higher highs and higher lows in place.

  • Business Wire19 days ago

    Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018

    Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter ended June 30, 2018 before the US financial markets open on July 26, 2018.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit19 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Business Wire19 days ago

    Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The application is supported by comprehensive data from two rigorous Phase 3 clinical trials in the largest population of patients with PNH ever studied in Phase 3: more than 440 patients, which included patients who had never received a complement inhibitor, and patients who were stable on Soliris® (eculizumab) and switched to ALXN1210.

  • Is Alexion Pharmaceuticals Inc (NASDAQ:ALXN) A Financially Sound Company?
    Simply Wall St.21 days ago

    Is Alexion Pharmaceuticals Inc (NASDAQ:ALXN) A Financially Sound Company?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Alexion Pharmaceuticals Inc (NASDAQ:ALXN) a safer option. One reason being its ‘too big to fail’Read More...

  • ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?
    Zacks21 days ago

    ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?

    ALXN vs. RGNX: Which Stock Is the Better Value Option?

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Investopedia26 days ago

    3 Big Biotechs That Can Beat the Market

    Trading well below their one-year highs, big biotech stocks look set for a rebound as their fundamentals are showing signs of improvement. More stable product pricing environments, earnings improvement and successful new drug trials, are just a few of the factors that could lead to a biotech rally in the second half of the year, with firms like Gilead Sciences Inc. ( GILD), Alexion Pharmaceuticals Inc. ( ALXN) and Vertex Pharmaceuticals Inc. ( VRTX) leading the charge.

  • Alexion (ALXN) Submits Application for ALXN1210 with FDA
    Zacks27 days ago

    Alexion (ALXN) Submits Application for ALXN1210 with FDA

    Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
    Zacks27 days ago

    Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

    The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.

  • TheStreet.com27 days ago

    5 Stocks That Are Screaming Buys Right Now

    Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.

  • Future home of PTC, Alexion could sell for $450M
    American City Business Journals27 days ago

    Future home of PTC, Alexion could sell for $450M

    The 17-story office at 121 Seaport Blvd. will be the future headquarters of industrial software company PTC, which is relocating from Needham, and Alexion Pharmaceuticals, which is relocating from New Haven, Connecticut.

  • Why This Biotech Company Could Shock 2019 Sales Expectations
    Investor's Business Daily28 days ago

    Why This Biotech Company Could Shock 2019 Sales Expectations

    Alexion surprised Wall Street on Tuesday when it asked the FDA for an expedited review of its newest rare-disease drug, ALXN1210.

  • Business Wire28 days ago

    Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.

    Alexion Pharmaceuticals, Inc. (ALXN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). “This first regulatory submission is an important step toward our goal of establishing ALXN1210 as the new standard of care for patients with PNH, building on 10 years of proven efficacy and safety with Soliris®, and 25 years of leadership in complement biology,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion.

  • Barrons.comlast month

    Big Biotech Set for Earnings Blowout?

    Earlier this year, Oppenheimer's Hartaj Singh argued that earnings expectations were too high for big biotech companies heading into the first-quarter reporting season. Ahead of the reports, due out in mid-July, Singh argues that fundamentals for large-cap biotech, as well as sector sentiment are "slowly but surely improving," leading him to believe that the stocks could outperform, led by Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), and Vertex Pharmaceuticals (VRTX). For Gilead, he's upbeat about a more stable pricing environment for hepatitis C treatments, while investors are getting more interested in the company's "budding" immunology and nonalcoholic steatohepatitis (NASH) franchises, setting up an attractive risk-reward profile going into the second quarter.  Alexion reported "stellar" first-quarter earnings, and Singh sees another strong quarter ahead, and he wonders "when the Street will start giving management credit for relentless execution." Vertex is one of his favorite large-cap biotechs, and he sees a good report ahead, along with an update about the progress of its cystic-fibrosis drugs.

  • Business Wirelast month

    Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for presentation during the Late-Breaking Oral Session (at 11:45 a.m. CET) on Sunday, June 17, 2018 at the Annual Conference of the European Hematology Association (EHA) in Stockholm, Sweden. “We are very excited about EHA’s recognition of the robustness and importance of these data in complement inhibitor treatment-naïve patients.

  • Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
    Zackslast month

    Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

    Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.